CR20230382A - Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer - Google Patents

Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer

Info

Publication number
CR20230382A
CR20230382A CR20230382A CR20230382A CR20230382A CR 20230382 A CR20230382 A CR 20230382A CR 20230382 A CR20230382 A CR 20230382A CR 20230382 A CR20230382 A CR 20230382A CR 20230382 A CR20230382 A CR 20230382A
Authority
CR
Costa Rica
Prior art keywords
sup
cancer
treatment
bicyclic
tetrahydroazepine
Prior art date
Application number
CR20230382A
Other languages
English (en)
Inventor
Holger Kuehne
Bernd Kuhn
Adrian Britschgi
Roman Hutter
Marco Brandstaetter
Laetitia Janine Martin
Juergen Wichmann
Thomas Luebbers
Barbara Johanna Mueller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20230382A publication Critical patent/CR20230382A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona nuevos derivados de tetrahidroazepina bicíclicos que tienen la Fórmula general (I) <img alt="" src="data:image/png;base64,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 (***)
CR20230382A 2021-02-12 2022-02-10 Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer CR20230382A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21156877 2021-02-12
EP21186928 2021-07-21
PCT/EP2022/053257 WO2022171745A1 (en) 2021-02-12 2022-02-10 Bicyclic tetrahydroazepine derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
CR20230382A true CR20230382A (es) 2023-09-06

Family

ID=80461879

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230382A CR20230382A (es) 2021-02-12 2022-02-10 Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer

Country Status (13)

Country Link
EP (1) EP4291558A1 (es)
JP (1) JP2024506339A (es)
KR (1) KR20230146052A (es)
AU (1) AU2022221124A1 (es)
CA (1) CA3210553A1 (es)
CL (1) CL2023002362A1 (es)
CO (1) CO2023010694A2 (es)
CR (1) CR20230382A (es)
IL (1) IL304595A (es)
MX (1) MX2023009379A (es)
PE (1) PE20231505A1 (es)
TW (1) TW202246257A (es)
WO (1) WO2022171745A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033388A1 (en) * 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033389A1 (en) * 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943A (en) 1847-01-26 Harness-buckle
US533A (en) 1837-12-26 Truss for hermta
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1996003397A1 (en) 1994-07-21 1996-02-08 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
CA2216796C (en) 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
SK398A3 (en) 1995-07-06 1998-07-08 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
PL340800A1 (en) 1997-11-06 2001-02-26 American Cyanamid Co Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
WO2003031376A1 (en) * 2001-10-12 2003-04-17 Aventis Pharmaceuticals Inc. Solid phase synthesis of substituted 1,5-benzodiazepine-2-one and 1,5-benzothiazepine-2-one
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
DK2343320T3 (da) 2005-03-25 2018-01-29 Gitr Inc Anti-gitr-antistoffer og anvendelser deraf
DK2559690T3 (en) 2005-05-10 2016-04-25 Incyte Holdings Corp Modulators of indoleamine 2,3-dioxygenase and methods of use thereof
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
EP1971583B1 (en) 2005-12-20 2015-03-25 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
US20110176972A1 (en) 2008-05-29 2011-07-21 Saint-Gobain Centre De Recherches et D'Etudes Eur Cellular structure containing aluminium titanate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
LT3023438T (lt) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antikūnai
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
NZ602161A (en) 2010-03-04 2014-12-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
RU2710717C2 (ru) 2010-09-09 2020-01-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1ВВ
NO2694640T3 (es) 2011-04-15 2018-03-17
LT2699264T (lt) 2011-04-20 2018-07-10 Medimmune, Llc Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US9394263B2 (en) * 2012-08-09 2016-07-19 F. Hoffmann-La Roche Ag Substituted hetero-azepinones
WO2016139181A1 (en) * 2015-03-02 2016-09-09 Apeiron Biologics Ag Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases

Also Published As

Publication number Publication date
AU2022221124A1 (en) 2023-08-03
WO2022171745A1 (en) 2022-08-18
PE20231505A1 (es) 2023-09-26
CO2023010694A2 (es) 2023-08-18
TW202246257A (zh) 2022-12-01
AU2022221124A9 (en) 2024-05-23
CA3210553A1 (en) 2022-08-18
EP4291558A1 (en) 2023-12-20
CL2023002362A1 (es) 2023-12-29
IL304595A (en) 2023-09-01
KR20230146052A (ko) 2023-10-18
MX2023009379A (es) 2023-10-10
JP2024506339A (ja) 2024-02-13

Similar Documents

Publication Publication Date Title
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
MX2021005714A (es) Nuevos compuestos heterociclicos.
MX2023009379A (es) Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
DE602004021472D1 (en) Pyrimiidinverbindungen
IN2014KN02886A (es)
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
MX2023002224A (es) Compuestos heterociclicos.
AU2003228770A8 (en) Substituted pyrazolopyrimidines
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
CR20230566A (es) Derivados de triazina y su uso en el tratamiento del cáncer
TW200510317A (en) Caspase inhibitors and uses thereof
CR20220004A (es) Nuevos compuestos heterocíclicos
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2023012477A (es) Compuestos heterociclicos.
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
MX2023012907A (es) Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3).
CR20220478A (es) Derivados de benzodiazepinas como pam de gaba a gamma 1
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2023012187A (es) Derivados de fosforo como nuevos inhibidores de sos1.
GB0322510D0 (en) Novel compounds
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados